Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


Betting big on blood screens for early cancer detection

The American Society of Clinical Oncology (ASCO) just held their annual gathering in Chicago. The event coincided with some interesting new develo…


Nuclear technology saves lives, especially in Belgium!

Nuclear energy has become a part of our every day lives, but not solely for electricity production. Over the last century, nuclear technology has …

POPULAR TAGS

Dutch company acquired by MDxHealth

Written by DS on in the category news with the tags , , .


The Dutch biotech company NovioGendix is acquired by the Belgian company MDxHealth. MDxHealth will pay $ 8.8 million (€ 7.8 million) for the Nijmegen-based company. NovioGendix is a spin-off of the Radboud University that develops tests to screen for prostate cancer based on a urine sample.

The Walloon MDxHealth pays $ 280.000 in cash and $ 5.1 million in shares. The remaining $ 3.3 million will follow if NovioGendix reaches specific milestones. MDxHealth is led by Dutchman Jan Groen, who previously had a key role in Agendia – known for its breast cancer test MammaPrint. The two companies both focus on developing tests to diagnose prostate, bladder and kidney cancer.

MDxHealth will place a new test of NovioGendix on the market, which enables to diagnose a dangerous variant of prostate cancer more accurately. It is expected that this will result in less biopsies. A biopsy is a difficult procedure, in which tissue is removed via the urethra. Approximately 1.3 million of this kind of biopsies are carried out around the world every year.

MDxHealth intends to introduce the new test next year in the US and possibly this year on a small scale in Europe. The company expects to achieve revenues of $ 16 million to $ 20 million.
 

Read more about: , , .

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


Betting big on blood screens for early cancer detection

The American Society of Clinical Oncology (ASCO) just held their annual gathering in Chicago. The event coincided with some interesting new develo…


Nuclear technology saves lives, especially in Belgium!

Nuclear energy has become a part of our every day lives, but not solely for electricity production. Over the last century, nuclear technology has …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK Janssen Turnstone KU Leuven XpandInnovation Biowin Itera Life Science Flanders.bio V-Bio Ventures UGent

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.